{"filings":[{"id":815638,"accession_number":"0001193125-26-254590","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-06-03T11:30:16+00:00","items":["5.07","8.01"],"status":"ready","headline":"REGENXBIO shareholders reject executive stock option exchange; approve non-executive program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 2026 annual meeting, shareholders voted against executive stock option exchange: 21,021,531 against, 14,097,815 for.","Shareholders approved non-executive stock option exchange: 26,352,456 for, 8,853,230 against. Company commenced program on June 3.","Exchange offer runs June 3–July 1, 2026; eligible options must have exercise price ≥ $18.00.","Directors elected: Jean Bennett, Jerry Karabelas, Daniel Tassé; PwC ratified as auditor; advisory say-on-pay approved.","Program not expected to significantly change stock compensation expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77564,"accession_number":"0001193125-26-222768","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-05-14T11:15:16+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"REGENXBIO RGX-202 Phase III meets primary endpoint (p<0.0001); Q1 net loss $90.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Primary endpoint achieved: 93% of patients >10% microdystrophin expression at Week 12 (p<0.0001); average expression 71.1%.","Significant correlation between microdystrophin expression and functional improvement (NSAA, p=0.0002); supports surrogate endpoint for accelerated approval.","Q1 2026 net loss $90.1M ($1.72/share) vs prior-year net income $6.1M; revenue fell to $6.4M from $89.0M (prior year milestone).","Cash $150.5M at March 31 (vs $240.9M Dec 31); runway into early 2027; expects $100M AbbVie milestone upon first DR patient dosed in Q2 2026.","FDA lifted clinical hold on RGX-121; company preparing for RGX-202 BLA submission targeting potential accelerated approval in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105924,"accession_number":"0001193125-26-117913","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"REGENXBIO settles GSK sublicense fee dispute for $10M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company will pay $10.0M to GSK within 3 business days for alleged underpayment of sublicense fees.","Settlement includes mutual releases of past claims and certain future claims under the 2009 license agreement.","Company retains existing allocation methodology for future sublicense fee payments to GSK.","Dispute covered sublicense fees and royalties on amounts received from sublicensees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105923,"accession_number":"0001193125-26-092566","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q4 net loss $67.1M; FDA holds on RGX-121/111; RGX-202 data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $67.1M ($1.30/sh) vs $51.2M loss ($1.01/sh) in Q4 2024; FY net loss $193.9M ($3.76/sh).","Revenues for full year 2025 $170.4M (up from $83.3M in 2024) driven by Nippon Shinyaku partnership and royalty increases.","Cash and marketable securities $240.9M at Dec 31, 2025; expects operations funded into early 2027.","FDA placed clinical holds on RGX-121 and RGX-111; issued Complete Response Letter for RGX-121 BLA in Feb 2026.","RGX-202 for Duchenne: topline pivotal data expected early Q2 2026; pre-BLA meeting mid-2026. Sura-vec wet AMD data expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105922,"accession_number":"0001193125-26-043342","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA rejects REGENXBIO's RGX-121 BLA for MPS II; company plans resubmission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued CRL on Feb 7, 2026 for RGX-121 (clemidsogene lanparvovec) to treat MPS II (Hunter syndrome).","CRL cites uncertainty in defining neuronopathic population, external control comparability, and surrogate endpoint CSF HS D2S6.","FDA suggests new study, additional patients, longer follow-up, or untreated control arm; company calls it 'devastating'.","REGENXBIO plans to request Type A meeting and aim for BLA resubmission with additional data.","Company had believed it addressed FDA's concerns during BLA review; independent experts supported data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105921,"accession_number":"0001193125-26-026139","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places clinical hold on REGENXBIO's RGX-111 and RGX-121 gene therapies after neoplasm case","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Single neoplasm (intraventricular CNS tumor) found in 5-year-old asymptomatic patient 4 years post-RGX-111 dose; AAV vector integration detected near PLAG1 proto-oncogene.","RGX-121 placed on hold due to product, population, and risk similarities with RGX-111.","No neoplasms reported in 9 other RGX-111 or 32 RGX-121 patients.","CEO surprised by RGX-121 hold while investigation continues; confident in benefit-risk based on positive safety and efficacy data.","Company has not yet received full clinical hold letter and awaits FDA details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122185,"accession_number":"0001193125-25-268101","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO reports Q3 2025 net loss $61.9M; pipeline advances with key milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.9M ($1.20/sh) vs $59.6M ($1.17/sh) in Q3 2024; revenue $29.7M (+23% YoY).","Cash, equivalents $302M as of Sep 30, 2025; cash runway into early 2027.","RGX-202 Duchenne pivotal enrollment complete (n=30); topline early Q2 2026, BLA mid-2026.","RGX-121 (MPS II) PDUFA date Feb 8, 2026; CSF biomarker reduction >80% sustained at 1 year.","Sura-vec wet AMD pivotal enrollment complete (n=1,200+); topline Q4 2026."],"consensus_eps_estimate":-1.3316,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":140104000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138910,"accession_number":"0000950170-25-109829","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA extends PDUFA date for RGX-121 BLA to February 8, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PDUFA goal date extended from Nov 9, 2025 to Feb 8, 2026 for review of additional 12-month data from pivotal study (n=13).","No safety concerns raised; pre-license inspection completed with no observations.","Company to present updated pivotal data at ICIEM meeting in September 2025; commercial launch plans remain on track.","RGX-121 would be first potential one-time therapy for MPS II (Hunter syndrome); holds FDA Orphan, Rare Pediatric, Fast Track, RMAT designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138909,"accession_number":"0001193125-25-174947","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"REGENXBIO amends AbbVie deal; restructures $200M milestones, starts DR pivotal; Q2 net loss $70.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to AbbVie collaboration: $100M milestone upon first pt dosed in Phase IIb/III DR trial, additional $100M upon first pt in Phase III.","REGENXBIO to pay costs for Phase IIb of that trial; AbbVie to fund new Phase III wAMD study (ACHIEVE).","Q2 net loss $70.9M ($1.38/share) vs $53.0M loss year ago; revenue $21.4M, down from $22.3M.","Cash $363.6M at June 30, 2025; expects to fund operations into early 2027.","RGX-202 Duchenne pivotal enrollment accelerated, to complete Oct 2025; topline data 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156395,"accession_number":"0000950170-25-080986","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"REGENXBIO stockholders elect four Class I directors, approve 2025 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four Class I directors elected: Fox (27.99M for), Glucksmann (29.26M), Simpson (32.80M), Zachary (29.18M) until 2028.","Ratified PricewaterhouseCoopers as independent auditor for FY2025: 41.17M for, 39,375 against.","Advisory approval of named executive officer compensation: 32.58M for, 1.76M against.","Advisory vote on frequency: 'Every 1 Year' received 33.15M votes; company will hold annual say-on-pay votes.","Approved 2025 Equity Incentive Plan: 27.40M for, 6.97M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156394,"accession_number":"0001193125-25-122456","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"REGENXBIO closes up to $250M royalty bond with HCRx; $150M funded, cash runway into early 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $150M at closing; up to $250M total via three tranches, including $50M contingent on Zolgensma sales threshold by Apr 2027.","Royalty bond bears interest at 9.75% + 3-month SOFR (4.25% floor); repayment solely from royalties on Zolgensma, RGX-121, RGX-111, and NAV platform licensees.","Issued HCRx warrant for 268,096 shares at $14.92 (100% premium to 30-day VWAP), exercisable for 10 years.","Extends expected cash runway into early 2027, funding late-stage programs including RGX-121, RGX-202, and ABBV-RGX-314.","Retains future non-dilutive sources: potential Priority Review Voucher for RGX-121 and milestones from AbbVie and Nippon Shinyaku."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156393,"accession_number":"0000950170-25-069211","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q1 net income $6.1M; revenue up 471% to $89M on Nippon Shinyaku deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $6.1M ($0.12 EPS) vs net loss $63.3M ($1.38 loss) in Q1 2024.","Revenue $89.0M (vs $15.6M) driven by $71.8M license revenue from Nippon Shinyaku partnership.","Cash $272.7M; operations funded into 2H 2026; guidance excludes milestone payments and PRV.","RGX-202 Duchenne pivotal trial >50% enrolled; BLA submission on track for mid-2026.","FDA expected to accept BLA for clemidsogene lanparvovec (RGX-121) in May; potential 2025 approval."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":89012000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174830,"accession_number":"0000950170-25-038711","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO reports Q4 net loss $51.2M; BLA for RGX-121 submitted, Nippon Shinyaku partnership closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.2M ($1.01/sh) in Q4 2024 vs $62.9M; full year $227.1M ($4.59/sh) vs $263.5M. Revenue $83.3M vs $90.2M.","BLA for RGX-121 (MPS II) submitted; FDA approval expected 2H 2025. Nippon Shinyaku deal closed: $110M upfront, up to $700M milestones.","RGX-202 Duchenne pivotal trial nearly 50% enrolled; completion expected 2025, BLA mid-2026. Phase I/II data show favorable safety and functional improvement.","Cash and securities $244.9M at Dec 31, 2024 (vs $314.1M). With $110M Nippon upfront, cash runway into 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174829,"accession_number":"0001193125-25-045585","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"REGENXBIO closes strategic partnership with Nippon Shinyaku for MPS gene therapies","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Partnership closed for development/commercialization of RGX-121 (MPS II) and RGX-111 (MPS I) in US and Asia.","RGX-121 on track as first gene therapy for MPS II; potential FDA approval as early as late 2025.","CEO Curran Simpson highlights transformative potential for MPS patient populations.","No financial terms disclosed in this filing; partnership was previously announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174828,"accession_number":"0001193125-25-005659","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"REGENXBIO licenses RGX-121/RGX-111 to Nippon Shinyaku for $110M upfront, up to $700M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $110M, milestones up to $700M ($40M dev/reg, $660M sales), plus double-digit royalties on net sales in U.S. and Asia.","REGENXBIO retains 100% of proceeds from RGX-121 Priority Review Voucher; rolling BLA submitted, potential FDA approval late 2025.","Nippon Shinyaku to commercialize in Licensed Territory (U.S., Asia); REGENXBIO leads manufacturing and retains rest-of-world rights.","RGX-111 for MPS I (Hurler) also included; Phase 1/2 results promising. Deal expected to close by end of Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191778,"accession_number":"0001193125-24-273467","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"REGENXBIO initiates pivotal phase of RGX-202 Duchenne trial with positive functional data; signs $150M ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First five patients in Phase I/II showed stable/improved function on NSAA and timed tests, exceeding external natural history controls.","FDA alignment achieved on accelerated approval pathway; BLA submission expected in 2026.","Biomarker data: RGX-202 microdystrophin expression highest reported; no serious adverse events.","New ATM sales agreement with Leerink Partners for up to $150M common stock, replacing prior BofA facility.","Pivotal trial enrolling ambulatory patients aged 1+, first patient dosed; includes younger boys aged 1-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191777,"accession_number":"0000950170-24-122300","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q3 net loss $59.6M; cash $278.6M; RGX-202 pivotal trial initiation expected this month","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $59.6M ($1.17 EPS) vs $61.9M ($1.41 EPS) in Q3 2023.","Revenue $24.2M, down from $28.9M, driven by lower Zolgensma royalties ($23.9M vs $28.4M).","Cash, cash equivalents and marketable securities $278.6M as of Sep 30, 2024.","RGX-202 pivotal trial initiation and first functional data expected November 2024.","BLA submission for RGX-121 (MPS II) initiated, expected completion Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":62114000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208257,"accession_number":"0000950170-24-107367","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"REGENXBIO appoints Mitchell Chan as CFO; Vittal Vasista steps down after 15 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mitchell Chan appointed EVP, CFO effective Sept. 16, 2024; base salary $490K, 40% bonus target, $3M equity grant (75% options, 25% RSUs).","Vittal Vasista resigns after 15+ years; separation allowance $500,018 over 3 installments and up to 75% of 2024 targeted bonus.","Vasista will serve as advisor to CEO through Jan. 3, 2025; unvested equity forfeited after advisory period.","Chan brings 20 years biopharma finance experience; prior CFO of Viela Bio (led $3B Horizon acquisition) and operating partner at Catalio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208256,"accession_number":"0001193125-24-194111","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"REGENXBIO grants RSUs to CMO and CSO to promote stability during CEO transition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On August 1, 2024, REGENXBIO granted 58,386 RSUs to EVP/CMO Stephen Pakola and 58,867 RSUs to EVP/CSO Olivier Danos.","RSUs vest over two years with one-fourth vesting every six months, subject to continued service.","Grant aims to retain leadership during a period of CEO transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208255,"accession_number":"0000950170-24-089278","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q2 net loss $53M; advances RGX-202 pivotal and RGX-121 BLA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss of $53.0M ($1.05 per share); revenue $22.3M (up 12% YoY) on Zolgensma royalties.","Cash $327.3M at June 30, 2024; runway into 2026, excluding potential $200M AbbVie milestone.","RGX-202 (Duchenne): consistent high microdystrophin expression; EOP2 supports accelerated approval; pivotal trial start Q4 2024.","RGX-121 (MPS II): rolling BLA submission begins Q3 2024 under accelerated approval pathway.","ABBV-RGX-314 (diabetic retinopathy): EOP2 meeting accelerated to Q4 2024; global pivotal trial planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":37917000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225858,"accession_number":"0001193125-24-160146","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"REGENXBIO appoints COO Curran Simpson as CEO; founder Kenneth Mills becomes Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Curran Simpson, former COO, appointed President and CEO effective July 1, 2024; also named to Board.","Co-founder Kenneth Mills steps down as CEO, becomes Chairman of the Board; advisor until June 2025.","Simpson's compensation: base salary $610k, bonus target 60%, equity grant $2.5M (75% options, 25% RSUs).","Daniel Tassé appointed Lead Independent Director, replacing Jerry Karabelas.","Company reiterates cash guidance: $380.5M as of March 31, 2024, funding ops into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225857,"accession_number":"0000950170-24-068050","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"REGENXBIO annual meeting voting results; all three director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["George Migausky, Kenneth T. Mills, David C. Stump elected as Class III directors with 39.1M, 39.3M, and 35.0M votes for, respectively.","Ratification of PricewaterhouseCoopers as auditor for FY2024: 44.2M for, 58K against, 41K abstain.","Advisory approval of named executive officer compensation: 40.1M for, 727K against, 35K abstain, with 3.3M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225856,"accession_number":"0000950170-24-055656","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q1 net loss $63.3M; RGX-202 selects pivotal dose; cash $380.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.3M ($1.38 diluted EPS) vs $66.7M ($1.53) YoY; revenue $15.6M, down from $19.1M.","Cash, equivalents and marketable securities $380.5M (up from $314.1M), runway into 2026.","RGX-202 Duchenne: pivotal dose DL2 selected; second patient showed 20.9% microdystrophin expression, 90% CK reduction.","ABBV-RGX-314 DR: positive interim ALTITUDE data; end-of-Phase II meeting FDA Q1 2025; pivotal trial H1 2025.","RGX-121 BLA filing on track for 2024 via accelerated approval; potential Priority Review Voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":15622000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244961,"accession_number":"0001193125-24-064353","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"REGENXBIO prices upsized public offering of common stock and pre-funded warrants at $23.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 4,565,260 shares at $23.00 and 1,521,740 pre-funded warrants at $22.9999, with gross proceeds ~$140M.","Net proceeds expected ~$131.2M (or $150.9M if underwriters fully exercise 30-day option for 913,050 additional shares).","Underwriters include Morgan Stanley, Goldman Sachs, Barclays, and Stifel as joint book-running managers.","Pre-funded warrants have $0.0001 exercise price, are exercisable immediately, and do not expire.","Offering expected to close March 11, 2024, under shelf registration statement (File No. 333-269086)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244960,"accession_number":"0000950170-24-021130","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO reports Q4 net loss $62.9M, cash $314M; pipeline milestones for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $62.9M ($1.43/sh); full year net loss $263.5M ($6.02/sh); 2023 revenue $90.2M vs $112.7M in 2022.","Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2023; expected to fund operations into H2 2025.","ABBV-RGX-314 wet AMD subretinal pivotal trials on track for global submissions late 2025-early 2026; suprachoroidal data mid-2024.","RGX-202 Duchenne pivotal dose determination mid-2024; RGX-121 MPS II BLA filing planned for 2024 via accelerated approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":90242000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}